Is EBS or EVO more undervalued in 2026?

CirclFi compares Emergent BioSolutions Inc. (EBS) and Evotec SE (EVO) using 13 institutional-grade valuation models. EBS has a Quality of Company score of 8.3/10 while EVO scores 6.2/10.

Which is a better buy — EBS or EVO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EBS and EVO valuations compare?

EBS at $9.18 and EVO at $2.96 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EBS vs EVO Valuation Comparison 2026 — Intrinsic Value Analysis

EBS

Drug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc.

Quality

8.3

out of 10

Value Trap

SAFE

Price

$9.18

Last close

Models

12/13

Active

EVO

Drug Manufacturers - Specialty & Generic

Evotec SE

Quality

6.2

out of 10

Value Trap

SAFE

Price

$2.96

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	EBS Fair Value	EBS Upside	EVO Fair Value	EVO Upside
Bayesian DCF	Intrinsic	$25.49	+177.6%	$0.22	-92.8%
Earnings Power Value	Intrinsic	$52.15	+468.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$17.72	+93.0%	$1.12	-62.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EBS vs EVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EBS vs EVO — Which Stock Is More Undervalued?

EBS scores higher with a 8.3/10 quality rating vs EVO's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Emergent BioSolutions Inc. (EBS) and Evotec SE (EVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EBS currently trades at $9.18 with a QOC of 8.3/10, while EVO trades at $2.96 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).